Novo Nordisk Fonden
Novo Nordisk Fonden is a Danish philanthropic foundation that owns the Novo Nordisk Group and holds a controlling interest in Novonesis. Through its ownership and grant-making activities, it combines long-term stewardship of industrial assets with support for research, innovation, and education.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueFunding for research, innovation, education, and standalone projects.
Long-term control and governance of the Novo Nordisk Group and other holdings.
Returns and distributions from owned companies and financial assets.
Customers
The Foundation's direct beneficiaries are researchers, universities, and educational institutions that receive grants and project support. Indirectly, its governance and capital allocation activities affect the Novo Nordisk Group, Novonesis, and other affiliated holdings. Its grant process also serves expert committees and advisory bodies that review applications and shape funding decisions.
Universities and research centers that receive funding for scientific programs and projects.
Schools, training programs, and education initiatives supported through grants.
Novo Nordisk Group and other holdings that depend on long-term ownership and governance.
Standalone and strategic initiatives funded to advance science, health, and innovation.
Strategy
The Foundation's strategy is to allocate capital through grants while preserving long-term control of key industrial holdings. It uses committees, advisory panels, and peer review to direct funding toward research, innovation, and education with a high level of selection discipline.
The Foundation wants funding decisions to remain fair, expert-led, and mission aligned.
Controlling holdings require stable governance and capital allocation over many years.
Grant funding is the main way the Foundation advances its charitable mission.
Geography
Novo Nordisk Fonden is headquartered in Denmark and its activities are anchored there through governance, ownership, and grant administration. The Foundation supports projects internationally, but the report excerpt does not provide a formal geographic revenue split. Its exposure is therefore tied less to sales geography than to the countries where funded research, owned subsidiaries, and related stakeholders operate.
Risks
The main risks are concentration in a small number of major holdings and dependence on the quality of governance and grant selection. As a foundation, it also faces legal, regulatory, and reputational risk around ownership rights, related-party transactions, and the fairness of grant allocation.
- Concentration in major holdingsImpact: HighLikelihood: High
A large share of value and governance influence is tied to a small number of affiliated companies.
Exposure - Grant-awarding disputesImpact: MediumLikelihood: Medium
Funding decisions rely on committee judgment and eligibility rules, which can be challenged.
Exposure: Research and education grants
- Regulatory and legal challengeImpact: MediumLikelihood: Medium
The report notes legal challenges related to the 340B program and changing legal landscape for related matters.
Exposure: Related ownership structures
Accounting
Judgemental itemsExpenses are recorded when the Foundation becomes obligated, affecting period-to-period comparability.
Impact: Can shift reported operating results across periods
The Foundation owns Novo Holdings and indirectly controls major industrial interests.
Impact: Determines which entities are included in group accounts
Returns from owned companies and investments are a key source of inflow.
Impact: Affects reported income and distributable capacity
Financial assets and liabilities may require valuation estimates.
Impact: Can create volatility in reported equity and profit
Last updated: 24/10/2026